173 related articles for article (PubMed ID: 24165426)
1. Doublets versus single-agent therapy as first-line therapy for elderly patients with advanced non-small cell lung cancer? A systematic review of randomised controlled trials.
Xu CA; Chang ZY; Wang XJ; Qi HY
Int J Clin Pract; 2013 Nov; 67(11):1118-27. PubMed ID: 24165426
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis comparing doublet and single cytotoxic agent therapy as first-line treatment in elderly patients with advanced nonsmall-cell lung cancer.
Wang S; Wang Q; Tian J; Zhou Z; Jiao L; Fu Y; Chen S; Zhang J; Xu L
J Int Med Res; 2015 Dec; 43(6):727-37. PubMed ID: 26438014
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
Des Guetz G; Uzzan B; Nicolas P; Valeyre D; Sebbane G; Morere JF
Crit Rev Oncol Hematol; 2012 Dec; 84(3):340-9. PubMed ID: 22534083
[TBL] [Abstract][Full Text] [Related]
4. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Qi WX; Tang LN; He AN; Shen Z; Lin F; Yao Y
Lung; 2012 Oct; 190(5):477-85. PubMed ID: 22711060
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis.
Russo A; Rizzo S; Fulfaro F; Adamo V; Santini D; Vincenzi B; Gebbia N; Carreca I
Cancer; 2009 May; 115(9):1924-31. PubMed ID: 19235250
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Pan G; Ke S; Zhao J
Target Oncol; 2013 Jun; 8(2):107-16. PubMed ID: 23516098
[TBL] [Abstract][Full Text] [Related]
7. [A meta analysis of doublets versus single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer].
Xu C; Chang Z; Wang X; Li L; Qi H; Liu Y
Zhongguo Fei Ai Za Zhi; 2012 Jun; 15(6):361-8. PubMed ID: 22681923
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
Rajeswaran A; Trojan A; Burnand B; Giannelli M
Lung Cancer; 2008 Jan; 59(1):1-11. PubMed ID: 17720276
[TBL] [Abstract][Full Text] [Related]
9. What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis.
Bronte G; Rolfo C; Passiglia F; Rizzo S; Gil-Bazo I; Fiorentino E; Cajozzo M; Van Meerbeeck JP; Lequaglie C; Santini D; Pauwels P; Russo A
Crit Rev Oncol Hematol; 2015 Sep; 95(3):306-17. PubMed ID: 25922216
[TBL] [Abstract][Full Text] [Related]
10. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials.
Hotta K; Matsuo K; Ueoka H; Kiura K; Tabata M; Tanimoto M
Ann Oncol; 2004 Dec; 15(12):1782-9. PubMed ID: 15550583
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis: Evaluation of safety and efficacy of the epidermal growth factor receptor-tyrosine kinase inhibitor monotherapy versus platinum-based doublets chemotherapy in East Asia.
Zhang XF; De-Sheng LV; Li M; Sun GE; Liu CH
Indian J Cancer; 2017; 54(1):104-114. PubMed ID: 29199672
[TBL] [Abstract][Full Text] [Related]
12. Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A meta-analysis of 42 RCTs following the PRISMA guidelines.
Wang J; Li G; Yu L; Mo T; Wu Q; Zhou Z
J Ethnopharmacol; 2018 Jul; 221():137-150. PubMed ID: 29655852
[TBL] [Abstract][Full Text] [Related]
13. Platinum rechallenge in patients with advanced NSCLC: a pooled analysis.
Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Ardine M; Barni S
Lung Cancer; 2013 Sep; 81(3):337-342. PubMed ID: 23891507
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
Qi WX; Shen Z; Yao Y
Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy analysis of third-generation plus platinum doublets in the first-line chemotherapy of advanced non-small cell lung cancer].
Zhao LD; Zhang XR; Li JL; Wang ZP; Wang Y; Hao XZ; Hu XS; Zhou SY; Sun Y; Shi YK
Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(22):1527-31. PubMed ID: 22944054
[TBL] [Abstract][Full Text] [Related]
16. Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis.
Horiuchi K; Sato T; Kuno T; Takagi H; Hirsch FR; Powell CA; Fukunaga K
Lung Cancer; 2021 Jun; 156():59-67. PubMed ID: 33894495
[TBL] [Abstract][Full Text] [Related]
17. Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: a meta-analysis.
Luo L; Hu Q; Jiang JX; Yang X; Dinglin XX; Lin X; Yao HR
Asia Pac J Clin Oncol; 2015 Sep; 11(3):253-61. PubMed ID: 25866140
[TBL] [Abstract][Full Text] [Related]
18. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
[TBL] [Abstract][Full Text] [Related]
19. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis.
Delbaldo C; Michiels S; Syz N; Soria JC; Le Chevalier T; Pignon JP
JAMA; 2004 Jul; 292(4):470-84. PubMed ID: 15280345
[TBL] [Abstract][Full Text] [Related]
20. Elemene injection as adjunctive treatment to platinum-based chemotherapy in patients with stage III/IV non-small cell lung cancer: A meta-analysis following the PRISMA guidelines.
Wang X; Liu Z; Sui X; Wu Q; Wang J; Xu C
Phytomedicine; 2019 Jun; 59():152787. PubMed ID: 31005810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
